Ensysce Biosciences announced an agreement with Purisys to scale the manufacture of the Company’s lead opioid use disorder drug candidate. PF9001, as recently announced, is a novel agent developed with Ensysce’s unique TAAP technology to treat OUD that will potentially decrease the cardiovascular side effects associated with methadone. Purisys brings experience with established manufacturing expertise specializing in commercial scale supply of complex synthetic compounds specifically in controlled substance chemistry.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENSC: